Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 230-237

  Rayla, Suresh K ^a   Mascarenhas, Joseph ^a   Vadlamudi, Ratna K ^a,b   Kumar, Rakesh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; COMPLEMENTARY DNA; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROLINE GLUTAMIC ACID LEUCINE RICH PROTEIN 1; PROTEIN BCL 2; REGULATOR PROTEIN; TAMOXIFEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL ASSAY; CELL CLONE; CELL CYCLE; CELL GROWTH; CELL LABELING; CELL LEVEL; CELL NUCLEUS; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; DNA VECTOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644985493     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0276     Document Type: Article

References (51)

1. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18: 3172-86.
2. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53:25-71.
3. Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 1995;6:498-507.
4. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring. J Steroid Biochem Mol Biol 2000;74:255-9.
5. Osborne CK. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7:4338-42s.
6. Barnes CJ, Vadlamudi RK, Kumar R. Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 2004;61:281-91.
7. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003;4:46-56.
8. Revelli A, Massobrio M, Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 1998;19:3-17.
9. Levin ER. Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001;91:1860-7.
10. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002;90:3-6F.
11. Iwase H, Omoto Y, Toyama T, et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat 2003;80: 339-45.
12. Vadlamudi RK, Wang RA, Mazumdar A, et al. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α. J Biol Chem 2001;276:38272-9.
13. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004;64:6416-23.
14. Vadlamudi RK, Balasenthil S, Broaddus R, Gustafson J, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 2004; 89:6130-8.
15. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in cancer cells. Cancer Res 2005;65:7724-32.
16. Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ER-β expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 2005;36: 670-5.
17. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003;14:185-91.
18. Palladino MA, Jr., Shalaby MR, Kramer SM, et al. Characterization of antitumor activities of human tumor necrosis factor α and the comparison with other cytokines: induction of tumor specific immunity. J Immunol 1987;138:4023-32.
19. Mishra SK, Balasenthil S, Nguyen D, Vadlamudi RK. Cloning and functional characterization of PELP1/MNAR promoter. Gene 2004;330: 115-22.
20. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274: 787-9.
21. Dhillon NK, Mudryj M. Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun 2003;4: 336-42.
22. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447-54S.
23. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids 2000;65:579-84.
24. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
25. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12:362-7.
26. Belizario JE, Tilly JL, Sherwood SW. Caffeine potentiates the lethality of tumor necrosis factor in cancer cells. Br J Cancer 1993;67: 1229-35.
27. Malorni W, Rainaldi G, Tritarelli E, et al. Tumor necrosis factor α is a powerful apoptotis inducer in lymphoid leukemia cells expressing p-170 glycoprotein. Int J Cancer 1996;67:238-47.
28. Jeoung DI, Tang B, Sonenberg M. Effects of tumor necrosis factor-α on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 1995;270:18367-73.
29. Cai Z, Bettaieb A, Mahdani NE, et al. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-α-mediated cytotoxicity. J Biol Chem 1997;272:6918-26.
30. Jurgenmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredsen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95:4997-5002.
31. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004; 6:203-8.
32. Shishodia S, Aggarwal BB. Nuclear factor-κB: a friend or a foe in cancer? Biochem Pharmacol 2004;68:1071-80.
33. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005;12:S37-46.
34. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
35. Nakshatri H, Bhat Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 2003;23:6887-900.
36. Gu Z, Lee RY, Skaar TC, et al. Association of Interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res 2002;62:3428-37.
37. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of Fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608.
38. Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005;4:33-41.
39. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004;87:167-80.
40. Baichwal VR, Baeuerle PA. Apoptosis: activate NF-κB or die? Curr Biol 1997;7:R94-6.
41. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
42. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
43. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs. Ann N Y Acad Sci 2004;1028: 104-12.
44. Rossi CR, Mocellin S, Pilati P, et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 2005;12: 398-405.
45. Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-α in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats. Anticancer Res 2005;25:743-50.
46. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-induce promoter, carrying the human tumor necrosis factor a gene: a phase 1 study in patients with solid tumors. J Clin Oncol 2004;22:592-601.
47. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
48. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-αV integrin ligands improves its antineoplastic activity. Cancer Res 2004;64:565-71.
49. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNF α to tumor blood vessels. Blood 2003;102:4384-92.
50. Eggermont AM, ten Hagen TL. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 2003;5:79-80.
51. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005;16:35-53.